Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Primary objective: · Part A/Phase I: The primary objective is to determine the safety and tolerability of twice daily oral doses of AZD2281 when administered in combination with cisplatin to patients with advanced solid tumours. · Part B/Phase II: The primary objective is to assess the complete pathological response rates of AZD2281+ cisplatin versus cisplatin alone in the treatment of patients with Triple Negative Breast Cancer in the neoadjuvant setting.
Critère d'inclusion
- Tumores sólidos avanzados, cáncer de mama triple negativo,Advanced Solid Tumours, Triple Negative Breast Cancer